Thymosin Alpha-1: What the Evidence Actually Shows

Thymosin Alpha-1 is a naturally occurring 28-amino-acid immunomodulatory peptide, marketed internationally as Zadaxin for hepatitis B/C and as an immune adjuvant. Unlike most compounds in this site's non-board corpus, it has a genuinely international regulatory history — but that history has a real, specific gap this article checked precisely rather than assumed: it has never received FDA marketing approval in the United States.

What it is, and how it's actually used

Thymosin alpha-1 is derived from prothymosin alpha, a 113-amino-acid precursor protein, and occurs naturally in the thymus, where it has long-recognized roles in enhancing, modulating, and restoring immune function. Its synthetic pharmaceutical form, thymalfasin, is administered by subcutaneous injection — as Zadaxin, it ships as a lyophilized powder in single-dose vials (1.6 mg thymosin alpha-1 per vial), reconstituted with 1 mL of sterile water for injection immediately before dosing. That is the real vial-and-diluent product this site's calculator page below models — a genuinely different market form than three of the other four compounds in this same five-compound research batch, none of which ship as an injectable at all.

The international approval record — real, and precisely sourced

A peer-reviewed 2020 review states plainly: "The synthetic form of thymosin alpha 1, thymalfasin, is approved in more than 35 countries for the treatment of hepatitis B and C¹." That figure comes from a peer-reviewed article, not a manufacturer's marketing page. Real trial data backs at least part of that approval history: a 2011 meta-analysis pooling 7 randomized controlled trials (535 patients total) found interferon plus thymosin alpha-1 combination therapy significantly outperformed interferon alone for HBeAg-positive chronic hepatitis B across every outcome measured — HBV-DNA clearance (54.9% vs. 36.3% at end of treatment, rising to 58.6% vs. 30.7% at follow-up), ALT normalization, and HBeAg loss/seroconversion rates, all with the combination arm ahead by a wide margin². This is a genuinely more substantial positive human trial record than most compounds in this site's non-board corpus carries.

The U.S. side of the split, checked precisely — not just repeated

The same 2020 review's own wording is imprecise in a way worth flagging directly rather than repeating: it states "FDA approved the orphan drug thymalfasin (Zadaxin)" for several indications — language that reads as a marketing-approval claim but is actually describing FDA's ORPHAN DRUG DESIGNATION, a distinct status that grants development incentives without approving a product for sale. This article checked that distinction independently rather than taking the review's phrasing at face value: openFDA's own Drugs@FDA database — the federal government's own record of approved drug applications — returns zero matches for "thymalfasin" as a generic name and zero matches for "Zadaxin" as a brand name³. No New Drug Application of any kind is on file. DailyMed's structured-product-label search independently confirms the same conclusion from a different database: zero results for "thymalfasin"⁴ — no FDA-approved U.S. drug label exists. Two independent federal database checks agree, and together they correct the review's own loose phrasing: Zadaxin has never received FDA marketing approval, whatever orphan-designation history it may carry separately, while it genuinely is an approved, marketed drug in more than 35 other countries. This is a real "approved elsewhere, not here" regulatory position, distinct from most compounds this site covers.

A real sepsis trial — reported at the precision it earned

Beyond hepatitis, thymosin alpha-1's most substantial other human trial is ETASS, a 361-patient multicenter randomized controlled trial testing it as an add-on therapy for severe sepsis in six Chinese ICUs. The result deserves to be stated at exactly the precision it earned: 28-day all-cause mortality was 26.0% in the thymosin alpha-1 group versus 35.0% in the control group, but the trial's own primary nonstratified analysis was not conventionally significant (P = 0.062) — only a secondary log-rank analysis crossed the P = 0.05 threshold (P = 0.049)⁵. That is a real, borderline signal in a genuine 361-patient RCT, not a clean positive result, and this article reports it as borderline rather than rounding it up.

FDA's compounding-safety page — the same discrepancy pattern as two siblings in this batch

Checked live for this article, FDA's current 503A Bulks List (updated May 14, 2026) contains no match for "thymosin" or "thymalfasin" in any category⁶. FDA's companion significant-safety-risk page, fetched live, DOES list a "Thymosin-alpha 1 (Ta1)" row, stating: "Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization⁷." One document omits it; the other still names it — the same discrepancy shape this batch's Selank article, and the existing Semax article, both independently document for their own compounds. openFDA's FAERS database returns 197 total reports for "THYMALFASIN"⁸ — a substantial reporting history, consistent with genuine international clinical use.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell Thymosin Alpha-1 — this site's own identity-layer research confirms it is not tagged to any reviewed seller. It is genuinely injectable, and ships as a real lyophilized-powder vial requiring reconstitution, which is why — unlike four of the other five new compounds this site added in this same research pass — it gets a /calculator/thymosin-alpha-1 reconstitution page. Its human evidence is real and comparatively substantial: a positive 7-trial, 535-patient hepatitis B meta-analysis, and a borderline-significant 361-patient sepsis RCT. Its regulatory position is genuinely split, and this article reports that split at the precision it deserves: approved in more than 35 countries internationally, but never FDA-approved for marketing in the United States — a real gap between international and U.S. approval status, not resolved by a since-lapsed orphan-drug designation. If you're researching other immune-modulatory peptides this site covers, our VIP evidence review covers a different immunomodulatory neuropeptide with a much thinner formal trial base and no approved product in any country.